- Home
- HBNC vs MLTX Comparison
HBNC vs MLTX Comparison
Compare HBNC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | MLTX |
|---|---|---|
| Founded | 1873 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 979.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HBNC | MLTX |
|---|---|---|
| Price | $16.86 | $11.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $19.67 | ★ $36.33 |
| AVG Volume (30 Days) | 425.4K | ★ 1.5M |
| Earning Date | 01-21-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $7.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $12.70 | $5.95 |
| 52 Week High | $18.70 | $62.75 |
Technical Indicators
Market Signals| Indicator | HBNC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 32.28 |
| Support Level | $16.41 | $11.06 |
| Resistance Level | $17.13 | $14.12 |
| Average True Range (ATR) | 0.38 | 0.74 |
| MACD | -0.20 | -0.31 |
| Stochastic Oscillator | 19.21 | 1.84 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.